Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
14 Apr 2020 02:06 PM
RNS
Second Price Monitoring Extn
14 Apr 2020 02:00 PM
RNS
Price Monitoring Extension
14 Apr 2020 11:05 AM
RNS
Second Price Monitoring Extn
14 Apr 2020 11:00 AM
RNS
Price Monitoring Extension
09 Apr 2020 04:41 PM
RNS
Second Price Monitoring Extn
09 Apr 2020 04:37 PM
RNS
Price Monitoring Extension
08 Apr 2020 02:05 PM
RNS
Second Price Monitoring Extn
08 Apr 2020 02:00 PM
RNS
Price Monitoring Extension
08 Apr 2020 11:05 AM
RNS
Second Price Monitoring Extn
08 Apr 2020 11:00 AM
RNS
Price Monitoring Extension
08 Apr 2020 09:05 AM
RNS
Second Price Monitoring Extn
08 Apr 2020 09:00 AM
RNS
Price Monitoring Extension
08 Apr 2020 07:00 AM
RNS
Avacta & Cytiva Collaborate on COVID-19 Rapid Test
06 Apr 2020 05:45 PM
RNS
Holding(s) in Company
06 Apr 2020 02:06 PM
RNS
Second Price Monitoring Extn
06 Apr 2020 02:01 PM
RNS
Price Monitoring Extension
06 Apr 2020 07:00 AM
RNS
Proposed Placing to raise £3.75 million
02 Apr 2020 07:01 AM
RNS
Appointment of Joint Broker
02 Apr 2020 07:00 AM
RNS
Subscription to raise £2 million
26 Mar 2020 11:05 AM
RNS
Second Price Monitoring Extn
26 Mar 2020 11:00 AM
RNS
Price Monitoring Extension
24 Mar 2020 02:06 PM
RNS
Second Price Monitoring Extn
24 Mar 2020 02:00 PM
RNS
Price Monitoring Extension
16 Mar 2020 04:42 PM
RNS
Second Price Monitoring Extn
16 Mar 2020 04:38 PM
RNS
Price Monitoring Extension
10 Mar 2020 07:00 AM
RNS
Shareholder/Investor Meeting and Presentation
13 Feb 2020 07:00 AM
RNS
Notice of Results
11 Feb 2020 07:00 AM
RNS
Share Incentive Plan/Issue of Equity
03 Feb 2020 07:00 AM
RNS
Avacta and Daewoong Agreement
29 Jan 2020 02:45 PM
RNS
Holding(s) in Company
28 Jan 2020 07:00 AM
RNS
Successful initial proof-of-concept
23 Jan 2020 07:00 AM
RNS
Trading Update
21 Jan 2020 07:00 AM
RNS
Director Appointment
08 Jan 2020 07:00 AM
RNS
Avacta and Daewoong Establish Joint Venture
26 Nov 2019 09:00 AM
RNS
Holding(s) in Company
22 Nov 2019 08:41 AM
RNS
Director/PDMR Shareholding
13 Nov 2019 07:00 AM
RNS
LG Chem Life Sciences Expands Partnership
11 Nov 2019 07:00 AM
RNS
Holding(s) in Company
08 Nov 2019 06:30 PM
RNS
Holding(s) in Company
08 Nov 2019 06:26 PM
RNS
Holding(s) in Company
07 Nov 2019 01:00 PM
RNS
Holding(s) in Company
07 Nov 2019 11:00 AM
RNS
Holding(s) in Company
06 Nov 2019 02:30 PM
RNS
Holding(s) in Company
04 Nov 2019 01:18 PM
RNS
Result of General Meeting
18 Oct 2019 12:06 PM
RNS
Proposed Placing & Subscription to raise up to £9M
18 Oct 2019 12:05 PM
RNS
Interim Results for the Period Ended 31 July 2019
10 Oct 2019 07:00 AM
RNS
Collaboration with ADC Therapeutics
05 Aug 2019 09:05 AM
RNS
Second Price Monitoring Extn
05 Aug 2019 09:00 AM
RNS
Price Monitoring Extension
29 Jul 2019 07:00 AM
RNS
Avacta's CEO to Present at Biotech Investor Day

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100